Related Experiment Video
Updated: Jul 11, 2026
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Combination treatment for acute ischemic stroke: A ray of Hope?
S C Fagan1, M P Bowes, S A Berri
1College of Pharmacy and Allied Health Professions, Wayne State University Center Detroit, MI. USA; Department of Pharmacy Services Center for Stroke Research Henry Ford Hospital and Health Science Center, Detroit, MI, USA; Department of Neurology, Center for Stroke Research Henry Ford Hospital and Health Science Center, Detroit, MI, USA; Department of Neurosciences, University of California, San Diego, CA. USA.
Background:
With the implementation of thrombolysis, a large number of distinct pharmacological agents are now under consideration for the treatment of acute ischemic stroke, with disappoiting early results. Because the processes that ultimately lead to ischemic cell death involve a variety of pathophysiologic pathways, it is likely that combinations of agents may be necessary to positively affect neurological outcome. We review the general strategies under consideration for reduction of ischemic injury in the central nervous system, the types of possible interactions between compounds, and the experimental evidence showing effective combination therapies.
Summary Of Review:
Reduction of ischemic injury has been attempted by the following pharmacologic mechanisms: thrombolysis, neuroprotection, and perfusion/reperfusion enhancers. There is experimental evidence that the combination of thrombolytic therapy with a neuroprotective agent is additive in some ischemic models, as is the combination of a thrombolytic with an agent that facilitates reperfusion (thromboxane A(2) receptor antagonist and neutrophil adhesion/activation inhibition). Combinations of neuroprotective agents such as glutamate antagonists and calcium channel antagonists may be additive, and other combinations of neuroprotective agents, such as a glutamate antagonist with a gamma-aminobutyric acid (GABA) agonist, have even shown synergism in a rat stroke model. It has also been suggested that lower doses of toxic drugs may be used together to yield a positive neurologic outcome. Successful demonstration of additive or synergistic effects of pharmacologic agents in ischemia will depend on (1) the model used (well below a maximal "ceiling effect"); (2) the timing of drug administration; (3) the doses of the drugs used; and (4) the primary neurologic endpoint used. (Infarction size requires prolonged survival.)
Conclusions:
It appears from preclinical studies that some combinations of pharmacotherapeutic agents may be beneficial in cerebral ischemia, but rigorous evaluation is needed before initiating clinical trials.
Insights
Combining therapies may improve acute ischemic stroke treatment. Preclinical studies suggest that combining thrombolysis with neuroprotection or reperfusion enhancers shows promise for better neurological outcomes.
Area of Science:
- Neuroscience
- Pharmacology
- Cerebrovascular Disease
Background:
- Acute ischemic stroke treatment faces challenges with current single-agent therapies.
- Complex pathophysiologic pathways in ischemic cell death necessitate combination approaches.
- Review of strategies for reducing central nervous system ischemic injury.
Purpose of the Study:
- To review general strategies for reducing ischemic injury in the central nervous system.
- To explore potential interactions between pharmacological agents.
- To examine experimental evidence for effective combination therapies in cerebral ischemia.
Main Methods:
- Review of preclinical studies on pharmacological interventions for ischemic stroke.
- Analysis of combination strategies including thrombolysis, neuroprotection, and perfusion enhancers.
- Evaluation of experimental evidence for additive and synergistic effects.
Main Results:
- Combination therapy of thrombolysis with neuroprotection or reperfusion enhancers shows additive effects in ischemic models.
- Combinations of neuroprotective agents, like glutamate antagonists and calcium channel blockers, may be additive.
- Synergistic effects observed with combinations such as glutamate antagonists and gamma-aminobutyric acid (GABA) agonists in a rat stroke model.
Conclusions:
- Preclinical evidence suggests potential benefits of combined pharmacotherapeutic agents in cerebral ischemia.
- Rigorous evaluation of combination therapies is crucial before clinical application.
- Optimizing drug combinations requires careful consideration of models, timing, dosage, and endpoints.
Related Concept Videos
01:15Ischemic Stroke l: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:17Hemorrhagic Stroke l: Introduction
01:15Ischemic Stroke ll: Pathophysiology
01:26Transient Ischemic Attack l: Introduction
01:27Coronary Artery Disease V: Interprofessional Care